BR0209327A - Composição para tratamento de constipação induzida por drogas - Google Patents

Composição para tratamento de constipação induzida por drogas

Info

Publication number
BR0209327A
BR0209327A BR0209327-8A BR0209327A BR0209327A BR 0209327 A BR0209327 A BR 0209327A BR 0209327 A BR0209327 A BR 0209327A BR 0209327 A BR0209327 A BR 0209327A
Authority
BR
Brazil
Prior art keywords
drug
composition
induced constipation
treatment
present
Prior art date
Application number
BR0209327-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23104042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0209327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BR0209327A publication Critical patent/BR0209327A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0209327-8A 2001-05-02 2002-04-26 Composição para tratamento de constipação induzida por drogas BR0209327A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28772001P 2001-05-02 2001-05-02
PCT/JP2002/004223 WO2002089812A1 (en) 2001-05-02 2002-04-26 Composition for treating drug-induced constipation with 15-keto-prostaglandins

Publications (1)

Publication Number Publication Date
BR0209327A true BR0209327A (pt) 2004-07-20

Family

ID=23104042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209327-8A BR0209327A (pt) 2001-05-02 2002-04-26 Composição para tratamento de constipação induzida por drogas

Country Status (19)

Country Link
US (1) US6982283B2 (https=)
EP (1) EP1392318B1 (https=)
JP (1) JP4332353B2 (https=)
KR (1) KR100886598B1 (https=)
CN (1) CN1522147B (https=)
AR (2) AR035237A1 (https=)
AT (1) ATE355067T1 (https=)
AU (1) AU2002251554B2 (https=)
BR (1) BR0209327A (https=)
CA (1) CA2444103C (https=)
DE (1) DE60218451T2 (https=)
DK (1) DK1392318T3 (https=)
ES (1) ES2282408T3 (https=)
MX (1) MXPA03010019A (https=)
NO (1) NO335143B1 (https=)
NZ (1) NZ529187A (https=)
PT (1) PT1392318E (https=)
TW (1) TWI302100B (https=)
WO (1) WO2002089812A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9044510B2 (en) 2007-11-01 2015-06-02 Washington University Compositions and methods for treating pruritus
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
KR20140052389A (ko) 2012-10-24 2014-05-07 주식회사 아리바이오 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물
US20140116916A1 (en) 2012-10-31 2014-05-01 2294719 Ontario Limited Therapy for Constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN105777601A (zh) * 2014-12-26 2016-07-20 中国人民解放军第二军医大学 一种前列地尔衍生物及其药物制剂
AU2017241904A1 (en) * 2016-03-29 2018-10-18 Colonaryconcepts Llc Formulations for treating constipation
JP6957610B2 (ja) * 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW224942B (https=) 1990-04-04 1994-06-11 Adka Ueno Kk
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
ATE387204T1 (de) * 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt

Also Published As

Publication number Publication date
CA2444103A1 (en) 2002-11-14
WO2002089812A1 (en) 2002-11-14
CN1522147A (zh) 2004-08-18
TWI302100B (en) 2008-10-21
JP4332353B2 (ja) 2009-09-16
KR100886598B1 (ko) 2009-03-05
ATE355067T1 (de) 2006-03-15
ES2282408T3 (es) 2007-10-16
AU2002251554B2 (en) 2007-05-24
NO20034864D0 (no) 2003-10-31
US20030073746A1 (en) 2003-04-17
PT1392318E (pt) 2007-05-31
MXPA03010019A (es) 2004-02-12
CN1522147B (zh) 2010-05-12
US6982283B2 (en) 2006-01-03
NZ529187A (en) 2005-10-28
CA2444103C (en) 2010-06-08
AR035237A1 (es) 2004-05-05
EP1392318B1 (en) 2007-02-28
NO335143B1 (no) 2014-09-29
DE60218451T2 (de) 2007-11-08
AR100696A2 (es) 2016-10-26
NO20034864L (no) 2003-12-23
DE60218451D1 (de) 2007-04-12
DK1392318T3 (da) 2007-06-25
EP1392318A1 (en) 2004-03-03
JP2004527567A (ja) 2004-09-09
KR20040008168A (ko) 2004-01-28

Similar Documents

Publication Publication Date Title
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
UY26130A1 (es) Compuestos para tratar la obesidad
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR0113184A (pt) Implante artificial e processo para produzir o mesmo
BR0010113A (pt) Preparações para uso externo na pele
BR0315580A (pt) Derivados de metileno uréia
AR109263A2 (es) Composición que comprende moxidectina
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0012696A (pt) Composição oftálmica
WO2025024305A3 (en) Irak4 degraders and uses thereof
BR0106687A (pt) Composição para intensificar a permeação de agentes tópicos à pele
BRPI0516077A (pt) composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente
BRPI0411702A (pt) uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870220088950 DE 28/09/2022, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO TEM FUNDAMENTACAO LEGAL.